- Home
- PEG vs TAK Comparison
PEG vs TAK Comparison
Compare PEG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEG
- TAK
- Stock Information
- Founded
- PEG 1903
- TAK 1781
- Country
- PEG United States
- TAK Japan
- Employees
- PEG N/A
- TAK N/A
- Industry
- PEG Power Generation
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- PEG Utilities
- TAK Health Care
- Exchange
- PEG Nasdaq
- TAK Nasdaq
- Market Cap
- PEG 42.1B
- TAK 41.1B
- IPO Year
- PEG N/A
- TAK N/A
- Fundamental
- Price
- PEG $88.14
- TAK $12.94
- Analyst Decision
- PEG Buy
- TAK
- Analyst Count
- PEG 13
- TAK 0
- Target Price
- PEG $87.75
- TAK N/A
- AVG Volume (30 Days)
- PEG 2.1M
- TAK 1.8M
- Earning Date
- PEG 02-24-2025
- TAK 01-30-2025
- Dividend Yield
- PEG 2.72%
- TAK 4.90%
- EPS Growth
- PEG N/A
- TAK 49.73
- EPS
- PEG 4.07
- TAK 1.27
- Revenue
- PEG $10,430,000,000.00
- TAK $31,732,209,416.00
- Revenue This Year
- PEG N/A
- TAK $6.15
- Revenue Next Year
- PEG $5.71
- TAK $0.86
- P/E Ratio
- PEG $21.66
- TAK $20.23
- Revenue Growth
- PEG N/A
- TAK 9.43
- 52 Week Low
- PEG $56.85
- TAK $12.58
- 52 Week High
- PEG $95.22
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- PEG 58.54
- TAK 36.92
- Support Level
- PEG $83.25
- TAK $12.86
- Resistance Level
- PEG $86.55
- TAK $13.20
- Average True Range (ATR)
- PEG 1.41
- TAK 0.13
- MACD
- PEG 0.50
- TAK -0.01
- Stochastic Oscillator
- PEG 88.27
- TAK 12.71
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and other nonregulated businesses such as nuclear power generation and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.